Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of KN3835 vs Placebo in the Treatment of Flexible/Semi-Flexible Hammertoe

NCT07759362 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT07759362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07759362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of KN3835 vs Placebo in the Treatment of Flexible/Semi-Flexible Hammertoe
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 3
Overall status
Recruiting
Start date
August 11, 2026
Completion date
December 31, 2027
Enrollment
554 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

flexible hammertoe, semi-flexible hammertoe